UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

The New England journal of medicine, 2013-08, Vol.369 (8), p.722-731

2013

Volltextzugriff (PDF)

Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature

Frontiers in oncology, 2023-02, Vol.13, p.1111706

2023

Volltextzugriff (PDF)

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus

Lung cancer (Amsterdam, Netherlands), 2015-02, Vol.87 (2), p.89-95

2015

Volltextzugriff (PDF)

Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit

Clinical medicine (London, England), 2019-03, Vol.19 (2), p.s54-s54

2019

Volltextzugriff (PDF)

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Volltextzugriff (PDF)

A decade long insight into patient views on kidney cancer care delivery

BJU international, 2024-09

2024

Volltextzugriff (PDF)

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

European urology, 2016-03, Vol.69 (3), p.450-456

2016

Volltextzugriff (PDF)

Trends in whole-brain radiotherapy and survival outcomes in the era of molecular testing in lung cancer

Royal College of Radiologists Open, 2023-12, Vol.1, p.100039, Article 100039

2023

Volltextzugriff (PDF)

Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience

Lung cancer (Amsterdam, Netherlands), 2021-06, Vol.156, p.S38

2021

Volltextzugriff (PDF)

Renal mass biopsy — a practical and clinicopathologically relevant approach to diagnosis

Nature reviews. Urology, 2024-06

2024

Volltextzugriff (PDF)

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

Journal of clinical oncology, 2024-01, Vol.42 (3), p.312-323

2024

Volltextzugriff (PDF)

Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17083-e17083

2020

Volltextzugriff (PDF)

Impact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer

BJU international, 2021-12, Vol.128 (6), p.752-758

2021

Volltextzugriff (PDF)

Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19

Journal of cancer education, 2022-12, Vol.37 (6), p.1861-1869

2022

Volltextzugriff (PDF)

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4597-TPS4597

2021

Volltextzugriff (PDF)

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.275-275

2021

Volltextzugriff (PDF)

Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16578-e16578

2018

Volltextzugriff (PDF)

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

Clinical cancer research, 2013-12, Vol.19 (24), p.6924-6934

2013

Volltextzugriff (PDF)

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS5103-TPS5103

2020

Volltextzugriff (PDF)

Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy

European urology oncology, 2022-06, Vol.5 (3), p.373-374

2022

Volltextzugriff (PDF)

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

European urology open science (Online), 2022-01, Vol.35, p.54-58

2022

Volltextzugriff (PDF)

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

Annals of oncology, 2007-02, Vol.18 (2), p.376-380

2007

Volltextzugriff (PDF)

PNFLBA-16 FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY

The Journal of urology, 2017-04, Vol.197 (4), p.e917-e917

2017

Volltextzugriff (PDF)

A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC)

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.409-409

2015

Volltextzugriff (PDF)

Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma?

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16061-e16061

2017

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

ThemaNephrectomy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(10)
Oncology
(9)
Female
(7)
Male
(7)
Urology & Nephrology
(7)
Adult
(5)
Aged
(5)
Carcinoma, Renal Cell - Drug Therapy
(5)
Kidney Neoplasms - Drug Therapy
(5)
Kidney Neoplasms - Pathology
(5)
Middle Aged
(5)
Treatment Outcome
(5)
Biological And Medical Sciences
(4)
Cancer
(4)
Disease-Free Survival
(4)
Kidney Cancer
(4)
Medical Sciences
(4)
Renal Cell Carcinoma
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus

Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

A decade long insight into patient views on kidney cancer care delivery

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

Trends in whole-brain radiotherapy and survival outcomes in the era of molecular testing in lung cancer

Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience

Renal mass biopsy — a practical and clinicopathologically relevant approach to diagnosis

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place

Impact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer

Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion

Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

PNFLBA-16 FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY

A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC)

Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma?

Aktive Filter

Suchergebnisse filtern